This study shows multiple sclerosis (MS) costs over $3 billion annually, driven by rising prevalence. MS is a chronic, incurable neurological disease that imposes growing social and economic burdens. The report provides recommendations for government with a focus on improving care, access and research.

This report quantifies the cost of allergic disease in Australia by the economic and wellbeing impact of allergic disease on the person with allergic disease, the broader health system, the economy and the community. In 2024, it is estimated that allergic disease impacts approximately 8.2 million Australians, with an estimated total financial cost of $18.9...

Antimicrobial resistance is a critical global health challenge, threatening the effectiveness of modern medicine and increasing the risk of untreatable infections. This report summarises discussion at the 2024 Antimicrobial Subscription Model roundtable. The roundtable agreed on 10 key principles to guide the development of a pilot program for novel antimicrobials and its implementation in Australia.

Despite the severity of motor neurone disease (MND), people with MND face a fragmented and inequitable system of care. A major driver of inequity is an age-based divide in funding. This report aims to guide policy decisions that enhance care, support and quality of life for people living with this condition and their carers.

Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of disability and death in Australia, despite well-established prevention and treatment strategies. This treatable condition has become harder to manage than it should be, leading to preventable ASCVD events. With all the resources in place, the challenge is to bring them together into a cohesive model of...